DUALITYBIO-B has been included in the Hang Seng Composite Index and is expected to become a target for the Hong Kong Stock Connect
I'm PortAI, I can summarize articles.
DUALITYBIO-B has been included in the Hang Seng Composite Index, with the change to be implemented after the market closes on September 5 and effective from September 8. Huatai Securities pointed out that the company meets the standards for market capitalization, liquidity, and listing time, and is expected to be included in the Hong Kong Stock Connect. Its key product DB-1310 has been granted Fast Track designation by the FDA for the treatment of certain types of advanced non-small cell lung cancer
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments